Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?
作者信息
Terpos Evangelos, Trougakos Ioannis P, Karalis Vangelis, Ntanasis-Stathopoulos Ioannis, Sklirou Aimilia D, Bagratuni Tina, Papanagnou Eleni-Dimitra, Patseas Dimitrios, Gumeni Sentiljana, Malandrakis Panagiotis, Korompoki Eleni, Dimopoulos Meletios A
机构信息
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.
出版信息
Am J Hematol. 2021 Sep 1;96(9):E321-E324. doi: 10.1002/ajh.26248. Epub 2021 Jun 2.
Abstract
摘要
相似文献
1
Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?接受BNT162b2 mRNA疫苗或AZD1222疫苗的健康志愿者中针对SARS-CoV-2的中和抗体反应比较：AZD1222疫苗的第二剂是否应提前接种？
Am J Hematol. 2021 Sep 1;96(9):E321-E324. doi: 10.1002/ajh.26248. Epub 2021 Jun 2.
2
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.β 变异株 COVID-19 疫苗 AZD2816 和 AZD1222（ChAdOx1 nCoV-19）作为初免接种程序在巴西、南非、波兰和英国的未曾接种过疫苗的成年人中的免疫原性和安全性：一项随机、部分双盲、2/3 期非劣效免疫桥接研究。
Lancet Microbe. 2024 Aug;5(8):100863. doi: 10.1016/S2666-5247(24)00078-8. Epub 2024 Jun 12.
3
Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial.健康成年人适应 COVID-19 疫苗接种方案后对 SARS-CoV-2 的体液免疫反应：IMCOVAS 随机临床试验。
Vaccine. 2024 Nov 14;42(25):126117. doi: 10.1016/j.vaccine.2024.07.018. Epub 2024 Jul 16.
4
SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.SARS-CoV-2 mRNA 疫苗在免疫原性初免和预免疫人群中引发不同的反应。
Front Immunol. 2021 Sep 27;12:728021. doi: 10.3389/fimmu.2021.728021. eCollection 2021.
5
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.英夫利昔单抗与 IBD 患者对 BNT162b2 和 ChAdOx1 nCoV-19 SARS-CoV-2 疫苗的免疫原性降低有关。
Gut. 2021 Oct;70(10):1884-1893. doi: 10.1136/gutjnl-2021-324789. Epub 2021 Apr 26.
6
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.使用BNT162b2疫苗第三剂对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）进行中和
N Engl J Med. 2021 Oct 21;385(17):1627-1629. doi: 10.1056/NEJMc2113468. Epub 2021 Sep 15.
7
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.BNT162b2 新冠病毒疫苗与体液免疫应答及动力学的相关性：医护人员前瞻性、单中心、纵向队列研究。
Lancet Respir Med. 2021 Sep;9(9):999-1009. doi: 10.1016/S2213-2600(21)00220-4. Epub 2021 Jul 2.
8
Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.COVID-19 mRNA 疫苗在孕妇和哺乳期妇女中的免疫原性。
JAMA. 2021 Jun 15;325(23):2370-2380. doi: 10.1001/jama.2021.7563.
9
A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern.在 COVID-19 患者中接种一剂 mRNA 疫苗可提高针对 SARS-CoV-2 及关注变异株的中和抗体。
Cell Rep Med. 2021 Dec 14;3(1):100486. doi: 10.1016/j.xcrm.2021.100486. eCollection 2022 Jan 18.
10
Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.评估新冠疫苗需要标准化的中和抗体检测。
EBioMedicine. 2021 Nov;73:103677. doi: 10.1016/j.ebiom.2021.103677. Epub 2021 Nov 3.
引用本文的文献
1
Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis.COVID-19 疫苗在实体瘤患者中的免疫应答：一项荟萃分析。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2357424. doi: 10.1080/21645515.2024.2357424. Epub 2024 May 24.
2
Vaccine-elicited B- and T-cell immunity to SARS-CoV-2 is impaired in chronic lung disease patients.慢性肺病患者中，疫苗引发的针对新冠病毒的B细胞和T细胞免疫功能受损。
ERJ Open Res. 2023 Oct 16;9(5). doi: 10.1183/23120541.00400-2023. eCollection 2023 Sep.
3
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.成年癌症患者对新冠病毒疫苗全程接种和加强针的体液免疫反应受损，尤其是正在接受积极治疗的血液系统癌症患者：一项系统评价和荟萃分析。
Cancers (Basel). 2023 Apr 12;15(8):2266. doi: 10.3390/cancers15082266.
4
Vaccine-elicited B and T cell immunity to SARS-CoV-2 is impaired in chronic lung disease patients.慢性肺病患者对新冠病毒的疫苗诱导B细胞和T细胞免疫受损。
medRxiv. 2023 Jan 28:2023.01.25.23284971. doi: 10.1101/2023.01.25.23284971.
5
SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies.SARS-CoV-2 体液免疫反应在 B 细胞恶性肿瘤患者接受 BNT162b2 加强针后的变化。
Am J Hematol. 2022 Oct;97(10):1300-1308. doi: 10.1002/ajh.26669. Epub 2022 Aug 2.
6
Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies.接种 BNT162b2 mRNA 疫苗的血液恶性肿瘤移植患者体内 SARS-CoV-2 抗体和固有细胞因子减少。
Front Immunol. 2022 May 25;13:899972. doi: 10.3389/fimmu.2022.899972. eCollection 2022.
7
Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months.体液免疫对 BNT162b2 疫苗针对 SARS-CoV-2 变异体的反应在六个月后下降。
Front Immunol. 2022 May 2;13:879036. doi: 10.3389/fimmu.2022.879036. eCollection 2022.
8
Anti-SARS-CoV-2 Neutralizing Antibody Responses after Two Doses of ChAdOx1 nCoV-19 vaccine (AZD1222) in Healthcare Workers.医护人员接种两剂ChAdOx1 nCoV-19疫苗（AZD1222）后的抗SARS-CoV-2中和抗体反应
Infect Chemother. 2022 Mar;54(1):140-152. doi: 10.3947/ic.2022.0009.
9
Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients.评估免疫功能低下患者对SARS-CoV-2 mRNA疫苗反应的早期临床试验见解
Front Immunol. 2022 Mar 4;13:827242. doi: 10.3389/fimmu.2022.827242. eCollection 2022.
10
Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222.接种BNT162b2和AZD1222疫苗6个月后中和抗体反应的比较。
Biomedicines. 2022 Feb 1;10(2):338. doi: 10.3390/biomedicines10020338.
本文引用的文献
1
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.骨髓瘤老年患者在接种第一剂BNT162b2疫苗后对新冠病毒的中和抗体反应较低。
Blood. 2021 Jul 1;137(26):3674-3676. doi: 10.1182/blood.2021011904.
2
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.BNT162b2 mRNA新冠疫苗在慢性淋巴细胞白血病患者中的疗效
Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.
3
Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine.接种BNT162b2 mRNA疫苗后，医护人员和八旬老人针对新冠病毒的年龄和性别依赖性抗体反应。
Am J Hematol. 2021 Jul 1;96(7):E257-E259. doi: 10.1002/ajh.26185. Epub 2021 Apr 24.
4
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.一剂接种和加强针接种时间对 ChAdOx1 nCoV-19（阿斯利康）疫苗免疫原性和有效性的影响：四项随机试验的 pooled 分析。
Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19.
5
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
6
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.在年轻和老年成年人中进行的一次单盲、随机、对照、2/3 期试验中，观察 ChAdOx1 nCoV-19 疫苗在初免-加强免疫方案中的安全性和免疫原性（COV002）。
Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19.
Zotero 插件